Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

213 results about "Flu immunization" patented technology

CHO-S cell strain capable of stably expressing H5N1 hemagglutinin protein and construction method of CHO-S cell strain

The invention relates to a CHO-S cell strain capable of stably expressing H5N1 hemagglutinin protein and a construction method of the CHO-S cell strain, and belongs to the field of bioengineering.H5N1 hemagglutinin protein expression plasmids are obtained in an in-vitro synthesis and seamless cloning mode, 293T cells are transfected through the H5N1 hemagglutinin protein expression plasmids, and it is proved that the H5N1 hemagglutinin protein is expressed; the CHO-S cell strain capable of stably expressing the H5N1 hemagglutinin protein is obtained by transfecting CHO-S cells by using the H5N1 hemagglutinin protein expression plasmids and carrying out multiple rounds of cloning and screening, so that a basis is provided for obtaining H5N1 recombinant protein influenza vaccines.
Owner:WEIRUI BIOTECHNOLOGY (KUNMING) CO LTD +1

Broad-spectrum influenza A vaccine immunogen composition and application

The invention belongs to the technical field of vaccines and biology, and particularly relates to a broad-spectrum influenza A vaccine immunogen composition and application. The invention provides a nucleic acid molecule for coding an immunogenic peptide, wherein the immunogenic peptide comprises: M2 protein extracellular region (M2e) peptide fragments which are connected in series; a hemagglutinin protein stem region extracellular domain (HA2) peptide fragment derived from an H7N9 influenza virus subtype; multimerization of the motif peptide fragment; and optionally, one or more linker peptide fragments independently located between the peptide fragments, wherein the polynucleotide molecule comprises a coding nucleic acid of each peptide fragment. The broad-spectrum influenza A vaccine can induce an organism to generate antigen-specific immune response, a high-titer antibody can be generated 14 days after last inoculation, the broad-spectrum influenza A vaccine can completely protect and resist attack of various subtype influenza A viruses, and the broad-spectrum influenza A vaccine has a wide application prospect.
Owner:FUDAN UNIVERSITY

Influenza A virus-like particle for chimeric expression of novel coronavirus RBD protein as well as preparation method and application of influenza A virus-like particle

The invention belongs to the technical field of biological pharmacy, and particularly relates to influenza virus-like particles for chimeric expression of new coronavirus RBD protein as well as a preparation method and application of the influenza virus-like particles. The virus-like particle is prepared by embedding fusion protein on the surface of influenza virus M1, and the fusion protein comprises an HA2 segment of HA protein of influenza virus, an extracellular functional region of M2e matrix protein, a conserved region short peptide of nucleoprotein, and RBD tandem protein with mutated five sites of 417, 452, 478, 484 and 501 of new coronavirus; the virus-like particles can be used for preventing specific influenza and new crowns; the preparation method of the virus-like particles is simple and low in cost, the virus-like particles are good in immunogenicity and cross protectiveness, the preparation requirements of large-scale influenza vaccines can be met, the biological safety is high, and the immunity of an organism to various influenza viruses and new coronal viruses can be stimulated.
Owner:THE FIRST AFFILIATED HOSPITAL OF HENAN UNIV

Serum-free full-suspension MDCK (Madin Darby Canine Kidney) cell and application thereof in preparation of influenza vaccine

The invention discloses a serum-free full-suspension MDCK (Madin-Darby Canine Kidney) cell and application thereof in preparation of influenza vaccines, and belongs to the field of virology and biological medicines. The serum-free full-suspension MDCK cell is preserved in the China Center for Type Culture Collection, is classified and named as a canine kidney cell MDCK-JHS, and has a preservation number of CCTCC NO: C2024373. The invention further provides a method for culturing the influenza virus by using the cell line, high-titer amplification of the influenza virus can be realized, and the method is suitable for industrial production.
Owner:GUANGZHOU JIAHE BIOTECHNOLOGY CO LTD

Multivalent influenza mRNA vaccines

The present disclosure provides multivalent influenza vaccine compositions comprising at least three messenger RNAs (mRNAs) encoding a combination of influenza A and influenza B hemagglutinin (HA) antigens, wherein the mRNA encoding the HA antigen of the influenza A virus is present in a different ratio (w / w) than the mRNA encoding the influenza B virus, and methods of eliciting an immune response by administering said compositions. In particular, the disclosures relate to mRNA encoding these antigens formulated in a lipid nanoparticle (LNP).
Owner:SANOFI PASTEUR INC

Novel influenza nanoparticle vaccine as well as preparation and application thereof

The invention belongs to the field of biomedicine, and particularly discloses a nasal spray influenza vaccine as well as a preparation method and application thereof. The invention provides a nasal spray influenza vaccine. Fusion protein in the nasal spray influenza vaccine comprises influenza virus strain HA protein or fragments thereof, influenza virus protein epitopes and ferritin. The adjuvant may be a CpG1009 adjuvant to enhance humoral and cellular immunity. A vaccine composed of the fusion protein and a novel CpG adjuvant can induce generation of a strong challenge protection effect.
Owner:CHENGDU NANOMICROGEN BIOTECH CO LTD +1

Lentinan-based influenza vaccine adjuvant as well as preparation method and application thereof

The invention provides an influenza vaccine adjuvant based on lentinan as well as a preparation method and application thereof. The active ingredient of the vaccine adjuvant is lentinan, the lentinan is extracted from fresh lentinus edodes through a water extraction and alcohol precipitation method, no additional chemical modification is needed, the vaccine adjuvant can be used for preparing the influenza virus vaccine, and the influenza virus vaccine at least contains one of three inactivated influenza virus antigens, namely H1N1 A, H3N2 A and Victoria B. The invention also provides a vaccine preparation and a preparation method thereof, the vaccine preparation comprises the vaccine adjuvant and an influenza virus vaccine, the content of lentinan in the vaccine preparation is 4 mg / mL, and the vaccine preparation has an immunological enhancement effect.
Owner:CHENGDU UNIV

Application of broad-spectrum influenza virus polypeptide vaccine in preparation of medicine for preventing influenza virus infection and controlling influenza virus reinfection

The invention discloses application of a broad-spectrum influenza virus polypeptide vaccine in preparation of a medicine for preventing influenza virus infection and controlling influenza virus reinfection, and belongs to the technical field of biological medicine. The vaccine is designed on the basis of artificially synthesized polypeptide, a polypeptide sequence which is highly conservative and has immunocompetence is screened and optimized aiming at various subtype influenza virus proteins, a broad-spectrum polypeptide vaccine P125-H is constructed, and an Ii-Key technology and an MF59 adjuvant are applied to enhance immune response. The vaccine can effectively induce immune protection against H1N1 and H7N9 influenza A viruses, significantly reduce the virus load, reduce pathological injury to the lung and improve the survival rate. The P125-H vaccine is composed of three optimized polypeptides, has a cross protection effect on various influenza virus subtypes, has the potential of being developed into a broad-spectrum influenza vaccine, and provides a new technical scheme for coping with influenza virus variation and improving vaccine efficacy.
Owner:STATION OF VIRUS PREVENTION & CONTROL CHINA DISEASES PREVENTION & CONTROL CENT

Vectored DEV avian influenza h9 vaccines

PCT designated stage expiredWO2025044922A2HeterologousAntigen
The present invention relates to the field of animal health. Particularly, the present invention relates to a composition, comprising a modified Duck Enteritis Virus (DEV) which comprises and is capable of expressing a heterologous polynucleotide coding for an antigen of a chicken pathogen. Furthermore, the present invention relates to a composition, comprising the modified DEV as vector-vaccine for chicken, and the use thereof. More particularly, the present invention relates to a vaccine composition against a chicken pathogen, comprising a modified DEV that shows no or reduced pathogenicity in chicken.
Owner:BOEHRINGER INGELHEIM VETMEDICA CHINA CO LTD

Multivalent influenza mRNA vaccine

Provided is an isolated mRNA molecule, which contains a nucleotide sequence encoding a chimeric immunogenic polypeptide, wherein the chimeric immunogenic polypeptide contains an immunogenic fragment of hemagglutinin (HA) of influenza A H5N1, an immunogenic fragment of hemagglutinin (HA) of influenza A H1N1, and an immunogenic fragment of hemagglutinin (HA) of influenza B Victoria, which are linked to each other. Further provided are a composition and vaccine containing the mRNA, a fusion protein encoded thereby, and a method using same for inducing an immune response to influenza virus in a subject.
Owner:RINUAGENE BIOTECHNOLOGY CO LTD +1

Construction and identification method of influenza B DNA vaccine

The invention discloses a construction and identification method of an influenza B DNA vaccine, which comprises the following steps: step 1, downloading sequence information of an influenza B recommended strain B / Austria / 1359417 / 2021 in vaccine strain recommended components in 2022-2023, carrying out codon optimization on an HA gene of the strain, and then carrying out gene synthesis, and naming the gene as BHA; 2, highly conservative sequences of HA protein, M2e protein and NA protein are selected for series combination, gene synthesis is performed after codon optimization, and the gene is named as G3; 3, respectively extracting plasmid DNAs of the synthetic fragments for later use; 4, amplifying a target fragment by using a PCR technology so as to connect a carrier; and 5, carrying out a target gene and vector connection experiment. According to the present invention, the HA protein sequence of the DNA vaccine can be rapidly replaced by using the restriction enzyme cutting site, the preparation method is simple, the immunogenicity is good, the cross protection is good, the preparation cost is low, the preparation requirement of the large-scale influenza vaccine can be met, and the important scientific significance and the important social value are provided.
Owner:ACAD OF MILITARY SCI PLA CHINA ACAD OF MILITARY MEDICAL SCI INST OF MILITARY VETERINARY MEDICINE

Application of BAG6 gene in regulation of influenza virus replication

The invention discloses an application of a BAG6 gene in regulation of influenza virus replication. The invention provides any one of the following applications of the substance for inhibiting expression of the BAG6 gene or the encoded protein thereof: 1) preparing a product for expanding propagation of influenza virus; 2) preparing a product for promoting influenza virus replication; and 3) preparing a product for improving the expression quantity of the influenza virus related protein. Experiments prove that the function of the BAG6 gene encoding protein is lost, and the BAG6 gene encoding protein can be used for researching the cell biological function of the BAG6 protein and the action and mechanism in other viruses; in addition, the strain has the potential of being applied to influenza vaccine production. Besides, overexpression is carried out on the BAG6 protein, it is found that the BAG6 protein can inhibit the replication titer of the influenza virus and the expression of the protein, and the effect of the BAG6 protein in influenza virus replication is explored from the two aspects of knockout and overexpression.
Owner:CHINA AGRI UNIV

MDCK cell strain and application thereof in vaccine preparation

The invention relates to the technical field of biology, in particular to an MDCK cell strain and application of the MDCK cell strain in preparation of influenza vaccines. The invention provides an MDCK cell strain, the preservation number of which is CCTCC NO: C202504. The cell strain not only can maintain high sensitivity and high yield to influenza viruses and ensure the yield and quality of vaccines, but also can remarkably improve the biological safety of cell matrix influenza vaccines due to elimination of tumorigenicity risk, and has a good application prospect. And a key technical support is provided for promoting domestic research and development and marketing of influenza vaccines based on cell culture.
Owner:YUEYANG HUDEX PHARM LTD

Nucleic acid influenza vaccines and respiratory virus combination vaccines

Some aspects of the disclosure relate to vaccines (e.g., RNA vaccines (e.g., mRNA vaccines)) for seasonal influenza viruses as well as methods of using the vaccines. Also described are combination vaccines (e.g., RNA vaccines (e.g., mRNA vaccines)) for seasonal influenza viruses and other respiratory viruses (e.g., respiratory syncytial viruses and coronaviruses), as well as methods of using the vaccines.
Owner:MODERNATX INC

Construction and application of H7 subtype and H5 and H7 tetravalent avian influenza DNA vaccine

The invention relates to construction and application of H7 subtype and H5 and H7 tetravalent avian influenza DNA vaccines. The invention belongs to the field of molecular biology, and aims to provide a DNA (deoxyribonucleic acid) vaccine for providing efficient immune protection for H7 subtype avian influenza virus. Specifically, the invention discloses an H7 subtype avian influenza virus hemagglutinin protein, which has an amino acid sequence as shown in SEQ ID NO: 5 and / or SEQ ID NO: 6. The invention also discloses polynucleotide for coding the protein, and the polynucleotide has a sequence as shown in SEQ ID NO: 1 and / or SEQ ID NO: 2. The polynucleotide can be used for preparing a vaccine aiming at the current epidemic H7 subtype avian influenza virus. The H5 + H7 tetravalent DNA vaccine is obtained by combining the vaccine with a vaccine aiming at the H5 subtype, and the H5 + H7 tetravalent DNA vaccine can be used for prevention and control of current H5 subtype and H7 subtype avian influenza.
Owner:HARBIN VETERINARY RESEARCH INSTITUTE CHINESE ACADEMY OF AGRICULTURAL SCIENCES (CHINA ANIMAL HEALTH & EPIDEMIOLOGY CENTER HARBIN BRANCH CENTER)

An H3N2 influenza mRNA vaccine targeting the tandem HA and NA proteins and its preparation method

This invention provides an H3N2 influenza mRNA vaccine targeting the tandem HA and NA proteins and its preparation method, relating to the field of vaccine preparation technology. The H3N2 influenza mRNA vaccine is obtained by linking the conserved amino acid sequences of HA and NA of H3N2 with GGGSGGGSGGGSGGGS, and the amino acid sequence of the H3N2 influenza mRNA vaccine is shown in SEQ ID NO.1, and the nucleic acid sequence is shown in SEQ ID NO.2. This invention overcomes the shortcomings of existing technologies, improves the protective effect of the vaccine against H3N2 influenza, and enables it to better cope with immune evasion from the latest emerging H3N2 variants.
Owner:INST OF MEDICAL BIOLOGY CHINESE ACAD OF MEDICAL SCI

Influenza virus-like particles (VLPS) comprising hemagglutinin produced within a plant

A method for synthesizing influenza virus-like particles (VLPs) within a plant or a portion of a plant is provided. The method involves expression of influenza HA in plants and the purification by size exclusion chromatography. The invention is also directed towards a VLP comprising influenza HA protein and plants lipids. The invention is also directed to a nucleic acid encoding influenza HA as well as vectors. The VLPs may be used to formulate influenza vaccines, or may be used to enrich existing vaccines.
Owner:MEDICAGO INC

A kind of influenza virus vaccine and its application

The present invention relates to the field of medicine, and specifically discloses an influenza virus vaccine fusion protein, which is a fusion protein formed by connecting an HA antigen fragment encoded by an influenza HA antigen gene and an M2 extracellular region fragment (M2e; Membrane Protein (M2) Extracellular Region (M2e) in series with an Fc fragment encoded by a human immunoglobulin gene in series. The fusion protein of the present invention has higher antigenicity than a single HA antigen or a single M2 extracellular region fragment antigen, and the Fc fragment can improve protein purification efficiency and prolong the half-life of the antigen in vivo. Therefore, the influenza vaccine provided by the present invention has great advantages and great application value.
Owner:BEIJING HEALTH GUARD BIOTECHNOLOGY INC

Methods and compositions for pandemic influenza vaccine

Provided herein are RNA molecules encoding viral replication proteins and antigenic proteins or fragments thereof. Also provided herein are compositions that include RNA molecules encoding viral replication proteins and antigenic proteins or fragments thereof, and lipids. RNA molecules and compositions including them are useful for inducing immune responses.
Owner:ARCTURUS THERAPEUTICS INC

MULTIVALENT NANOPARTICLE INFLUENZA VACCINES

This document describes multivalent nanoparticle vaccine compositions suitable for use in influenza vaccines. The nanoparticles contain effective amounts of influenza glycoproteins that provide a greater immune response compared to a commercially available influenza vaccine composition. This description also provides vaccine formulation strategies that are cost-effective and convenient for clinical use. Methods for administering the nanoparticle vaccine compositions to a subject are also described.
Owner:NOVAVAX INC

An influenza vaccine transportation optimization method and system based on data driving

PendingCN122335154ACold chainFlu immunization
This invention provides a data-driven method and system for optimizing influenza vaccine transport, relating to the fields of data processing and intelligent optimization. The method includes acquiring multi-source dynamic data corresponding to the influenza vaccine transport task, and performing time alignment and feature construction on the multi-source dynamic data to obtain feature vectors representing a set of candidate transport links and a set of candidate transport nodes. The candidate transport links represent the transport modes and path combinations from the starting node to the destination node. This data-driven method and system for optimizing influenza vaccine transport establishes a data-driven machine learning prediction model by performing time alignment and feature construction on multi-source dynamic data such as road traffic, weather, transport node operational capabilities, and cold chain status. This model jointly predicts transport time, node waiting time, and temperature exceedance risks, achieving accurate characterization of the timeliness and cold chain risks in the influenza vaccine transport process.
Owner:DONGGUAN UNIV OF TECH

Dissociation liquid applied to aluminum adjuvant adsorption influenza vaccine and method for measuring antigen content

The invention belongs to the technical field of biological medicines, and particularly relates to a dissociation liquid applied to an aluminum adjuvant adsorption influenza vaccine and a method for measuring the antigen content. The dissociation liquid disclosed by the invention is prepared from a potassium phosphate salt solution, diethanol amine, TritonX-100, tween-20, dodecyl dimethyl betaine and water. The dissociation liquid is excellent in dissociation efficiency, the dissociation recovery rate of the dissociation liquid to H1N1, H3N2 and BV type influenza vaccine hemagglutinin reaches 106%-110%, the antigen activity can be effectively protected, operation is easy and convenient, adaptability is wide, a dissociated sample can be directly used for mainstream detection methods such as a one-way immunodiffusion test, an enzyme-linked immunosorbent assay and a high performance liquid chromatography method, and the dissociation liquid has good application prospects. The precise quantification of the antigen content in the aluminum adjuvant adsorption influenza vaccine is realized, and a reliable technical support is provided for vaccine quality control.
Owner:JIANDA BIOTECHNOLOGY (NANJING) CO LTD +2

Multivalent influenza nanoparticle vaccines

The present invention discloses multivalent nanoparticle vaccine compositions suitable for use in influenza vaccines. The nanoparticles comprise an effective amount of an influenza glycoprotein that provides an enhanced immune response as compared to commercially available influenza vaccine compositions. The invention also provides vaccine formulation strategies that are cost-effective and convenient for clinical use. Also disclosed are methods of administering the nanoparticle vaccine compositions to a subject.
Owner:NOVAVAX INC

H3n2 canine influenza recombinant virus strain and application thereof

The application belongs to the field of vaccines and genetic engineering technology, and relates to an H3N2 canine influenza recombinant virus strain and application thereof. Specifically, the application relates to a recombinant canine influenza vaccine strain which is obtained by recombination of the following genes: an HA gene, an NA gene, a PB1 gene, a PB2 gene, a PA gene, an NP gene, an M gene and an NS gene; wherein the sequence of the HA gene is shown as SEQ ID NO:1; and / or the sequence of the NA gene is shown as SEQ ID NO:2. The application also relates to an H3N2 canine influenza recombinant vaccine and a method for preparing the H3N2 canine influenza recombinant vaccine.
Owner:ACAD OF MILITARY SCI PLA CHINA ACAD OF MILITARY MEDICAL SCI INST OF MILITARY VETERINARY MEDICINE

Influenza vaccine

The present application provides vaccines comprising an inactivated influenza virus and an adjuvant comprising a triterpenoid saponin, a sterol, and an immunostimulatory oligonucleotide comprising CpG. Also provided are methods of using such vaccines.
Owner:ZOETIS SERVICES LLC

An adjuvanted influenza vaccine, its method of preparation and use

The application belongs to the technical field of biological medicine, and particularly relates to an adjuvant influenza vaccine and a preparation method and application thereof. The adjuvant influenza vaccine comprises an influenza virus monovalent stock solution, an adjuvant and a PBS buffer solution; the adjuvant is prepared by using mixed oil and an auxiliary agent, the mixed oil comprises squalene, medium-chain triglyceride and alpha-tocopherol; and the auxiliary agent comprises sorbitan trioleate Span-85, Tween 80 and vitamin E succinate polyethylene glycol ester. The adjuvant influenza vaccine prepared by the application has good immunization effect, and can especially improve the overall effect of a tetravalent adjuvant influenza vaccine on four viruses.
Owner:JIANGSU JINDIKE BIOTECHNOLOGY CO LTD